Zentralklinik Bad Berka GmbH
- Address
- lock Available on a paid plan
Neoplasms and Lung Cancer Research
At Zentralklinik Bad Berka GmbH, clinical trials in neoplasms focus heavily on non-small cell lung cancer, small cell lung cancer, and neuroendocrine tumors. The studies are designed to test new treatment options, compare therapies, and improve survival outcomes for people with advanced or metastatic disease.
- Advanced and metastatic non-small cell lung cancer
- Small cell lung cancer and extensive-stage SCLC
- Neuroendocrine neoplasms and pancreatic or gastroenteric tumors
- Evaluation of new anti-cancer combinations and targeted approaches
This research includes efforts to refine treatment effectiveness, extend disease control, and support better outcomes for patients with difficult-to-treat cancers.
Respiratory Tract Diseases and Pulmonary Fibrosis
The site also conducts substantial research in respiratory tract diseases, especially idiopathic pulmonary fibrosis, progressive pulmonary fibrosis, and chronic obstructive pulmonary disease. These trials aim to evaluate whether new therapies can slow lung function decline, improve symptoms, and offer longer-term safety and tolerability.
- Idiopathic pulmonary fibrosis and fibrotic lung disease
- Progressive pulmonary fibrosis
- COPD and other chronic lung conditions
- Testing treatments that may preserve breathing capacity and quality of life
The research portfolio reflects a strong interest in therapies that address both disease progression and day-to-day lung function in patients with chronic pulmonary illness.
Cardiovascular Diseases and Metabolic Risk
Trials in cardiovascular diseases at this hospital explore heart failure, hypercholesterolemia, and broader prevention of major cardiac events. The overall goal is to assess whether emerging treatments can reduce hospitalizations, lower cardiovascular risk, and improve outcomes in patients with complex heart and metabolic conditions.
- Heart failure with preserved or mildly reduced ejection fraction
- Hypercholesterolemia and elevated lipoprotein(a)
- Prevention of coronary events and other major cardiovascular complications
- Evaluating new options for patients with obesity-related cardiac risk
These studies support ongoing efforts to improve cardiovascular care through better prevention and more effective long-term disease management.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 therapeutic areas and 15 of 51 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 50 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 11 by active trials.
- 1Merck Sharp & Dohme LLC2active
lock +10 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Merck Sharp & Dohme LLC6trials
lock +4 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Zentralklinik Bad Berka GmbH
lock Showing 1 of 30 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2/3, multicenter, randomized open-label study of zanzalintinib vs everolimus in participants with previously treated, unresectable, locally advanced or metastatic neuroendocrine tumors | Exelixis Inc. | Phase IV | Recruiting | Jan 2026 | — |
IMP list
lock Showing 1 of 51 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 7 | Unknown | 2018-03-21 | 2025-07-08 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.